Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension:: The switch is possible

被引：4

作者：

Flox Camacho, Angela ^{[1
]}

Escribano Subias, Pilar ^{[1
]}

Tello de Meneses, Rocio ^{[1
]}

Delgado Jimenez, Juan ^{[1
]}

Gomez Sanchez, Miguel A. ^{[1
]}

Saenz de la Calzada, Carlos ^{[1
]}

机构：

[1] Hosp Univ 12 Octubre, Serv Cardiol, Unidad Hipertens Pulmonar Insuficiencia Cardiaca, Madrid, Spain

来源：

REVISTA ESPANOLA DE CARDIOLOGIA | 2006年 / 59卷 / 07期

关键词：

prostacyclin; bosentan; arterial pulmonary hypertension;

D O I：

10.1016/S1885-5857(07)60033-4

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Prostacyclin improves symptoms, exercise tolerance, and survival in patients with pulmonary arterial hypertension. However, the difficulty of administration (whether intravenous, subcutaneous, or by inhalation) often causes side effects that can reduce the patient's quality of life and which may sometimes be serious. Bosentan, an orally active endothelin receptor antagonist, improves functional class and exercise tolerance in these patients. We describe the successful transition from prostacyclin to bosentan in five patients with severe pulmonary arterial hypertension who suffered serious side effects with prostacyclin treatment.

引用

收藏

页码：737 / 739

页数：3

相关论文

共 9 条

[1]

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension [J].

Galiè, N ;

Seeger, W ;

Naeije, R ;

Simonneau, G ;

Rubin, LJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :81S-88S

[2]

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension [J].

Galiè, N ;

Hinderliter, AL ;

Torbicki, A ;

Fourme, T ;

Simonneau, G ;

Pulido, T ;

Espinola-Zavaleta, N ;

Rocchi, G ;

Manes, A ;

Frantz, R ;

Kurzyna, M ;

Nagueh, SF ;

Barst, R ;

Channick, R ;

Dujardin, K ;

Kronenberg, A ;

Leconte, I ;

Rainisio, M ;

Rubin, L .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) :1380-1386

[3]

García JM, 2004, REV ESP CARDIOL, V57, P1017

[4]

Drug therapy: Treatment of pulmonary arterial hypertension [J].

Humbert, M ;

Sitbon, O ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) :1425-1436

[5]

Kim NH, 2003, CHEST, V124, P1612, DOI 10.1378/chest.124.4.1612

[6]

Survival with first-line bosentan in patients with primary pulmonary hypertension [J].

McLaughlin, VV ;

Sitbon, O ;

Badesch, DB ;

Barst, RJ ;

Black, C ;

Gallè, N ;

Rainisio, M ;

Simonneau, G ;

Rubin, LJ .

EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (02) :244-249

[7]

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension [J].

Sitbon, O ;

Gressin, V ;

Speich, R ;

Macdonald, PS ;

Opravil, M ;

Cooper, DA ;

Fourme, T ;

Humbert, M ;

Delfraissy, JF ;

Simonneau, G .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (11) :1212-1217

[8]

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension - A 1-year follow-up study [J].

Sitbon, O ;

Basesch, DB ;

Channick, RN ;

Frost, A ;

Robbins, IM ;

Simonneau, G ;

Tapson, VF ;

Rubin, LJ .

CHEST, 2003, 124 (01) :247-254

[9]

Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension [J].

Suleman, N ;

Frost, AE .

CHEST, 2004, 126 (03) :808-815